Dalbavancin as chronic antibiotic suppression therapy for left ventricular assist device driveline infection due to methicillin-resistant Staphylococcus aureus : a case report.
Carlo PallottoSara TordiRomina PantanellaDaniele RosignoliDaniela FrancisciPublished in: Journal of chemotherapy (Florence, Italy) (2022)
Left Ventricular Assist Devices (LVADs) represent an important therapeutic option in the management of advanced heart failure. We report a case of 74 years-old male with a Jarvik 2000® (Jarvik Heart, New York, USA) LVAD who presented with an infection of the LVAD driveline due to methicillin-resistant Staphylococcus aureus (MRSA) that was treated with dalbavancin as chronic antimicrobial suppression therapy without adverse events and maintaining a good quality of life for more than 37 weeks. Dalbavancin could represent a valid option for the treatment of LVAD infections because of its efficacy, pharmacokinetic/pharmacodynamic proprieties, safety and tolerability.
Keyphrases
- methicillin resistant staphylococcus aureus
- left ventricular assist device
- heart failure
- staphylococcus aureus
- left ventricular
- atrial fibrillation
- open label
- acute myocardial infarction
- randomized controlled trial
- combination therapy
- mitral valve
- replacement therapy
- left atrial
- drug induced
- mesenchymal stem cells
- gestational age
- coronary artery disease
- bone marrow
- cell therapy
- catheter ablation